Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
Gobbini E, Ezzalfani M, Dieras V, Bachelot T, Brain E, Debled M, Jacot W, Mouret-Reynier MA, Goncalves A, Dalenc F, Patsouris A, Ferrero JM, Levy C, Lorgis V, Vanlemmens L, Lefeuvre-Plesse C, Mathoulin-Pelissier S, Petit T, Uwer L, Jouannaud C, Leheurteur M, Lacroix-Triki M, Cleaud AL, Robain M, Courtinard C, Cailliot C, Perol D, Delaloge S. Gobbini E, et al. Among authors: perol d. Eur J Cancer. 2018 Jun;96:17-24. doi: 10.1016/j.ejca.2018.03.015. Epub 2018 Apr 13. Eur J Cancer. 2018. PMID: 29660596
[Metastatic osteosarcoma: prognosis factors and treatment].
Mialou V, Philip T, Pérol D, Bérard P, Raimondo G, Pacquement H, Zucker JM, Kalifa C. Mialou V, et al. Among authors: perol d. Bull Cancer. 2001 Nov;88(11):1129-35. Bull Cancer. 2001. PMID: 11741807 Free article. French.
A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.
Cassier PA, Chabaud S, Trillet-Lenoir V, Peaud PY, Tigaud JD, Cure H, Orfeuvre H, Salles B, Martin C, Jacquin JP, Agostini C, Guastalla JP, Pérol D, Bachelot T. Cassier PA, et al. Among authors: perol d. Breast Cancer Res Treat. 2008 May;109(2):343-50. doi: 10.1007/s10549-007-9651-3. Epub 2007 Jul 5. Breast Cancer Res Treat. 2008. PMID: 17611792 Clinical Trial.
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.
Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Ray-Coquard I, et al. Among authors: perol d. Cancer Res. 2009 Jul 1;69(13):5383-91. doi: 10.1158/0008-5472.CAN-08-3845. Epub 2009 Jun 23. Cancer Res. 2009. PMID: 19549917 Free PMC article.
Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis.
Dufresne A, Bertucci F, Penel N, Le Cesne A, Bui B, Tubiana-Hulin M, Ray-Coquard I, Cupissol D, Chevreau C, Perol D, Goncalves A, Jimenez M, Bringuier PP, Blay JY. Dufresne A, et al. Among authors: perol d. Br J Cancer. 2010 Aug 10;103(4):482-5. doi: 10.1038/sj.bjc.6605783. Epub 2010 Jul 27. Br J Cancer. 2010. PMID: 20664593 Free PMC article. Clinical Trial.
200 results